Breaking News Instant updates and real-time market news.

AZN

AstraZeneca

$33.25

0.34 (1.03%)

19:07
11/14/17
11/14
19:07
11/14/17
19:07

AstraZeneca's FASENRA receives FDA approval

AstraZeneca announced that the US Food and Drug Administration has approved FASENRA for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype. FASENRA is not approved for the treatment of other eosinophilic conditions or relief of acute bronchospasm or status asthmaticus. Pascal Soriot, Chief Executive Officer of AstraZeneca, said: "We're excited to offer FASENRA as a new precision biologic to help improve the lives of severe asthma patients whose disease is driven by eosinophilic inflammation. This is the first approval from our respiratory biologics portfolio and the latest in a series of significant milestones for our company as we deliver on our pipeline-driven transformation."

  • 28

    Nov

AZN AstraZeneca
$33.25

0.34 (1.03%)

11/13/17
BMOC
11/13/17
NO CHANGE
BMOC
BMO says Pfizer buying Biogen makes more sense than deal for Bristol-Myers
BMO Capital analyst Alex Arfaei noted the "significant market speculation" that Pfizer (PFE) is preparing to execute a large M&A deal. While many sources, including Bloomberg, have speculated that Pfizer could target Bristol-Myers (BMY), Arfaei argues that a deal for Biogen (BIIB) would make more sense. He believes Pfizer has a significant gap in neurology, particularly in Alzheimer's, where it cannot afford to remain on the sidelines as its peers - including Biogen, Merck (MRK), AstraZeneca (AZN), and Eli Lilly (LLY) - all have pivotal trials in that area reading out in 2019-2020. Pfizer could have an opportunity to leverage near-term volatility in Biogen's MS franchise to strike a deal during the next 6-9 months before a potential interim look on aducanumab, which Arfaei views as the strongest of the next wave of Alzheimer's drugs in development, he tells investors.
10/16/17
10/16/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Apple (AAPL) was upgraded to Overweight from Sector Weight at KeyBanc and Pacific Crest. 2. Infinera (INFN) upgraded to Neutral from Sell at Citi with analyst Stanley Kovler saying the risk/reward is balanced with material downward revisions to estimates likely limited. 3. AstraZeneca (AZN) upgraded to Outperform from Neutral at Credit Suisse with analyst Rebekah Harper saying that after recent pipeline success for Tagrisso and Imfinzi, she sees a marked improvement in its strategic position in pricing power and replacement power. 4. KKR (KKR) upgraded to Buy from Neutral at Goldman Sachs with analyst Alexander Blostein citing a more stable, improving mix of balance sheet investments, lower concentration in large public holdings, and increased mix towards private holdings. 5. Groupon (GRPN) upgraded to Market Perform from Underperform at Cowen with analyst Thomas Champion saying he believes the shares currently look more attractive given the company's new management and cost controls, improved North America results, and balanced expectations for the second half of 2017. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/16/17
FBCO
10/16/17
UPGRADE
FBCO
Outperform
AstraZeneca upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Rebekah Harper upgraded AstraZeneca to Outperform from Neutral saying that after recent pipeline success for Tagrisso and Imfinzi, she sees a marked improvement in its strategic position in pricing power and replacement power.
09/25/17
RHCO
09/25/17
NO CHANGE
Target $19
RHCO
Buy
NewLink collaboration with AstraZeneca a validation, says SunTrust
SunTrust analyst Peter Lawson said NewLink Genetics' (NLNK) newly-announced collaboration with AstraZeneca (AZN) is the first "big pharma" partnership for NewLink's lead IDO pathway inhibitor. The deal adds external validation to an asset that is "trading at a fraction" of Incyte's IDO, said Lawson, who keeps a Buy rating and $19 price target on NewLink shares.

TODAY'S FREE FLY STORIES

MAC

Macerich

$63.61

0.075 (0.12%)

09:59
11/22/17
11/22
09:59
11/22/17
09:59
Rumors
Rumor moving shares of Macerich »

Rumor: Macerich strength…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KBR

KBR

$19.19

0.3402 (1.80%)

, FLR

Fluor

$47.67

0.11 (0.23%)

09:55
11/22/17
11/22
09:55
11/22/17
09:55
Periodicals
KBR takeover potential speculation floated by blog »

Shares of KBR (KBR) are…

KBR

KBR

$19.19

0.3402 (1.80%)

FLR

Fluor

$47.67

0.11 (0.23%)

APO

Apollo Global

$30.27

0.1094 (0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

SIG

Signet Jewelers

$54.48

1.69 (3.20%)

, FTR

Frontier Communications

$7.08

-0.15 (-2.07%)

09:55
11/22/17
11/22
09:55
11/22/17
09:55
Options
Early notable gainers among liquid option names on November 22nd »

Notable gainers among…

SIG

Signet Jewelers

$54.48

1.69 (3.20%)

FTR

Frontier Communications

$7.08

-0.15 (-2.07%)

BBBY

Bed Bath & Beyond

$20.27

-0.59 (-2.83%)

RRC

Range Resources

$17.56

0.38 (2.21%)

M

Macy's

$20.63

0.2113 (1.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

  • 20

    Dec

  • 18

    Mar

09:55
11/22/17
11/22
09:55
11/22/17
09:55
General news
FX Action: USD-JPY »

FX Action: USD-JPY has…

T

AT&T

$34.25

-0.08 (-0.23%)

, TWX

Time Warner

$89.74

0.18 (0.20%)

09:53
11/22/17
11/22
09:53
11/22/17
09:53
Conference/Events
FBN Securities strategist to hold an analyst/industry conference call »

FBN Securities…

T

AT&T

$34.25

-0.08 (-0.23%)

TWX

Time Warner

$89.74

0.18 (0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

CUB

Cubic

$62.00

1.25 (2.06%)

09:52
11/22/17
11/22
09:52
11/22/17
09:52
Technical Analysis
Technical View: Cubic up on mobile ticketing contract win for Rhein-Sieg area »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

SAN

Banco Santander

$6.49

0.09 (1.41%)

09:50
11/22/17
11/22
09:50
11/22/17
09:50
Options
Santander Mar 7 calls active at the opening bell Wednesday »

Santander Mar 7 calls…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XXII

22nd Century

$2.31

-0.0094 (-0.41%)

09:46
11/22/17
11/22
09:46
11/22/17
09:46
Hot Stocks
22nd Century to discontinue U.S. sales of RED SUN brand cigarettes »

22nd Century Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:45
11/22/17
11/22
09:45
11/22/17
09:45
General news
Consumer Sentiment Index to be reported at 10:00 »

Consumer Sentiment Index…

SAN

Banco Santander

, GME

GameStop

09:40
11/22/17
11/22
09:40
11/22/17
09:40
Options
Unusually active option classes on open November 22nd »

Unusual total active…

SAN

Banco Santander

GME

GameStop

HPE

HP Enterprise

HPQ

HP Inc.

CRM

Salesforce

SWKS

Skyworks

$110.25

0.46 (0.42%)

LRCX

Lam Research

$218.91

3.81 (1.77%)

SBUX

Starbucks

$57.26

0.45 (0.79%)

BIDU

Baidu

$244.30

5.76 (2.41%)

AMAT

Applied Materials

$58.80

1.18 (2.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 27

    Nov

  • 28

    Nov

  • 28

    Nov

  • 29

    Nov

  • 11

    Dec

  • 25

    Jan

XLE

Energy Select Sector SPDR

09:40
11/22/17
11/22
09:40
11/22/17
09:40
Technical Analysis
Technical View: Energy Select Sector SPDR leads index on the upside »

The Energy Select Sector…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOW

Lowe's

, HD

Home Depot

09:37
11/22/17
11/22
09:37
11/22/17
09:37
Recommendations
Lowe's, Home Depot analyst commentary  »

Lowe's price target…

LOW

Lowe's

HD

Home Depot

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

09:35
11/22/17
11/22
09:35
11/22/17
09:35
General news
U. Michigan sentiment preview: »

U. Michigan sentiment…

CHFS

CHF Solutions

$7.88

-0.24 (-2.96%)

09:31
11/22/17
11/22
09:31
11/22/17
09:31
Syndicate
CHF Solutions announces $18M public offering »

CHF Solutions announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTL

Mechel

09:31
11/22/17
11/22
09:31
11/22/17
09:31
Hot Stocks
Mechel announces reversal of Court decision »

Mechel reports a court…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:30
11/22/17
11/22
09:30
11/22/17
09:30
General news
The U.S. durables report undershot estimates »

The U.S. durables report…

09:30
11/22/17
11/22
09:30
11/22/17
09:30
General news
Breaking General news story  »

Week of 11/19 Bloomberg…

SNPS

Synopsys

$89.38

0.48 (0.54%)

09:29
11/22/17
11/22
09:29
11/22/17
09:29
Recommendations
Synopsys analyst commentary  »

Synopsys price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AQUA

Evoqua Water

09:26
11/22/17
11/22
09:26
11/22/17
09:26
Hot Stocks
Evoqua Water names Dan Brailer head of investor relations »

Evoqua Water announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROK

Rockwell Automation

, EMR

Emerson

09:26
11/22/17
11/22
09:26
11/22/17
09:26
Recommendations
Rockwell Automation, Emerson analyst commentary  »

Latest Rockwell rebuff…

ROK

Rockwell Automation

EMR

Emerson

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:25
11/22/17
11/22
09:25
11/22/17
09:25
General news
Fed funds futures are slightly firmer toward the back end of the curve »

Fed funds futures are…

PBYI

Puma Biotechnology

$104.90

0.85 (0.82%)

09:24
11/22/17
11/22
09:24
11/22/17
09:24
Hot Stocks
Puma Biotechnology, Specialised Therapeutics Asia enter licensing agreement »

Puma Biotechnology and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPE

HP Enterprise

09:22
11/22/17
11/22
09:22
11/22/17
09:22
Hot Stocks
Whitman 'definitively' says not running for President or any other office »

Meg Whitman, speaking in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 11

    Dec

PG

Procter & Gamble

09:22
11/22/17
11/22
09:22
11/22/17
09:22
Hot Stocks
Trian comments on Procter & Gamble's contest to voting tabulation »

Trian Fund Management,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DE

Deere

, SFL

Ship Finance

09:22
11/22/17
11/22
09:22
11/22/17
09:22
Hot Stocks
On The Fly: Pre-market Movers »

UP AFTER EARNINGS: Deere…

DE

Deere

SFL

Ship Finance

EMR

Emerson

ROK

Rockwell Automation

FRO

Frontline

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

  • 22

    Nov

  • 28

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.